Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use

Trial Profile

Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 May 2017

At a glance

  • Drugs OMS 721 (Primary)
  • Indications Thrombotic microangiopathy
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 17 May 2017 According to an Omeros Corporation media release, the company has established a compassionate-use program for OMS721, which is active in both the U.S. and Europe.
    • 10 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top